Related Articles
ADJUVANT CHEMOENDOCRINE THERAPY FOR EARLY BREAST-CANCER - IS IT WORTHWHILE - (REVIEW)
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy
Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer
A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein (Review)